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In recent years massive amounts of genomic information char-
acterizing the majority of human cancers have become available,
which has profoundly changed our perception of the complexity
of this disease. Huge efforts by The Cancer Genome Atlas
(TCGA) and the International Cancer Genome Consortium
(ICGC) projects have reshaped the landscape of mutations, tran-
scription signatures, epigenetic profiles and copy number chang-
es in cancer [1, 2]. Integrating this (epi-)genomic and
transcriptomic information with clinical data has led to a first
glimpse on inter- and intra-tumor heterogeneity in relation to
diagnosis, prognosis and response to therapy, and to the identi-
fication of novel targetable molecular alterations [3].We are now
facing a decennium in which we will be able to integrate the
currently used TNM system with novel molecular markers to
better classify and stage tumors, to better stratify patients and
to better use molecular markers to develop biology-based indi-
vidualized treatment options. In this special issue of Cellular
Oncology some key recent developments and points of concern
in the field of personalized cancer care are reviewed, including
which steps still need to be taken before the final implementation
of personalized cancer medicine becomes a clinical reality.
One of the major goals in the coming years will be the
identification of biological driver events in cancers for which
no targeted therapeutic options are available yet. Currently,
still the majority of patients with cancer are treated using stan-
dard therapies (i.e., surgery, radiotherapy, chemotherapy).
This is mostly due to the fact that targetable molecular alter-
ations have so far only been identified in a handful of cancer
types and in a minority of patients. Unsupervised molecular
classification of human cancers is increasingly leading to the
identification of driver molecular pathways and their associ-
ated clinical features. Salazar and colleagues [4] highlight in
this special issue how the integration of (epi-)genomic data in
an unsupervised manner can re-define the above mentioned
molecular heterogeneity present in human cancers at a deeper
level, and how this integration can reveal cross-talk between
molecular pathways. In this manner, colon, lung and breast
cancers have e.g. been re-classified into molecular subgroups
based on their biological characteristics and, concomitantly,
their newly identified targetable pathways. As a corollary of
this novel information, possible mechanisms of resistance to
targeted therapies have also been proposed. While so far most
studies have primarily focused on genomic (exomic) data, it is
becoming increasingly clear that not only mutations or copy
number changes are underlying the immense complexity of
human cancers. In this special issue Poliseno and colleagues
[5] nicely illustrate the emerging role and clinical significance
of a large group of regulatory RNAs, with special emphasis on
long-non-coding RNAs, pseudogenes and circular RNAs. The
authors illustrate via several examples the profound role that
these molecules can play in diverse human cancers, their po-
tential as diagnostic and prognostic markers, and their dual
role as both therapeutic agents and targets.
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Several technological developments have facilitated the in-
depth detection of large numbers of molecular alterations in a
single tumor in a relatively time- and cost-effective way, such
that these technologies can be implemented in both routine
research and clinical practice [6]. The clinical interpretation
of these vast amounts of information is, however, still chal-
lenging. Van Neste et al. [7] describe in this special issue the
importance of appropriate bioinformatics tools to make this
information manageable, interpretable and actionable, and
they also highlight the work that still needs to be done before
large genomic screens can be implemented in routine patient
care. Specifically, it is still a major challenge to effectively
separate driver from passenger events and to delineate genetic
and epigenetic alterations in the same pathway in an integrated
fashion. With the growing amount of (epi-)genomic informa-
tion that is generated per patient, the main challenges will be
to efficiently mine and combine independent data sets and to
make these data sets meaningful for a broader audience.
Another challenge that lies at the basis of both future re-
search and the translation and clinical implementation of its
findings into tools for personalized medicine, is the organiza-
tion of health care itself. The logistics of assembling and han-
dling samples is another major issue. To this end, Nuciforo
and colleagues [8] emphasize in this special issue how sample
collection, storage and processing, biological heterogeneity
and study design can profoundly influence the results and
the interpretation of the molecular findings in the context of
routine clinical diagnostics and trials.
In order to circumvent invasive methods multiple initia-
tives are currently ongoing, including studies aimed at using
circulating tumor cells or tumor DNAs or, alternatively, mo-
lecular imaging. In this special issue Mammatas et al. [9]
introduce the potential role of molecular imaging in personal-
ized cancer medicine and provide an overview of recent de-
velopments in this field. They emphasize that molecular im-
aging is a non-invasive method that can be extremely useful to
study a tumor’s heterogeneity and response to therapy.
Response to therapy does not only depend on the (ectopic)
expression of certain proteins and drug uptake by the tumor,
but can also be influenced by germline variants in genes in-
volved in drug metabolism and transport, a field of study
named pharmacogenomics. Testing for these variants may re-
sult in increased drug efficacy through adapting drug doses to
personal needs. In this special issue Pesenti et al. [10] review
recent developments in the field of pharmacogenomics and
provide an overview of germline variants that can be tested
in clinical practice and, thus, can be employed to contribute to
personalized cancer medicine.
While tremendous efforts in recent years have paved the
way for the next step in personalized biology-driven cancer
medicine in the genomic era, major challenges are still lying
ahead of us. Once these challenges have been turned into
opportunities for the application of diagnostic tests and per-
sonalized treatment options, the prospect glimmers on the ho-
rizon for the medical community to offer the best practice to
cancer patients.
References
1. G. Ciriello, M.L. Miller, B.A. Aksoy et al., Emerging landscape of
oncogenic signatures across human cancers. Nat Genet 45, 1127–
1133 (2013)
2. International Cancer Genome Consortium, T.J. Hudson, W.
Anderson et al., International network of cancer genome projects.
Nature 464, 993–998 (2010)
3. A. Geurts van Kessel, The cancer genome: from structure to function.
Cell Oncol 37, 155–165 (2014)
4. C. Santos, C. Sanz-Pamplona, E. Nadal, et al., Intrinsic cancer sub-
types. Next steps into personalized medicine. Cell Oncol. 38(1)
(2015). doi: 10.1007/s13402-014-0203-7
5. M. Vitiello, L. Poliseno, Long non coding RNAs in cancer: implica-
tions for personalised therapy. Cell Oncol. 38(1) (2015). doi: 10.
1007/s13402-014-0180-x
6. A. Geurts van Kessel, New insights and clinical advancements in
cellular oncology. Cell Oncol 35, 139–147 (2012)
7. L. Van Neste, W. van Criekinge, We are all individuals… bioinfor-
matics in the personalized medicine era. Cell Oncol. 38(1) (2015).
doi: 10.1007/s13402-014-0195-3
8. L. Prudkin, P. Nucifero, Obstacles to precision oncology: confronting
current factors affecting the successful introduction of biomarkers to
the clinic. Cell Oncol. 38(1) (2015). doi: 10.1007/s13402-014-0192-
6
9. L.H. Mammatas, H.M. Verheul, N.H. Hendrikse, et al., Molecular
imaging of targeted therapies with positron emission tomography:
the visualization of personalized cancer care. Cell Oncol. 38(1)
(2015). doi: 10.1007/s13402-014-0194-4
10. L. Pesenti, M. Gusella, S.M. Sirchia et al. , Germline
oncopharmacogenetics, a promising field in cancer therapy. Cell
Oncol. 38(1) (2015). doi: 10.1007/s13402-014-0214-4
2 S. Derks, B. Diosdado
